Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Emergent BioSolutions has entered a five-year agreement with Johnson & Johnson unit Janssen Pharmaceutical for large-scale manufacturing of drug substance for the latter’s Covid-19 vaccine candidate, Ad26.COV2-S.
As part of the deal, Emergent agreed to offer contract development and manufacturing (CDMO) services for drug substance production, valued at about $480m for the initial two years.
The company will start delivering manufacturing services for the Ad26.COV2-S vaccine in 2021, after the activities covered by the previously executed technology transfer agreement are complete.